A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
Adult Onset Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Adult Onset Rheumatoid Arthritis focused on measuring MEDI4920, VIB4920, CD40L, RA, rheumatoid arthritis
Eligibility Criteria
Inclusion Criteria:
- adult-onset rheumatoid arthritis
- swollen and tender joints
Exclusion Criteria:
- venous thromboembolism or arterial thrombosis
- pregnant or breastfeeding
- positive hepatitis B, hepatitis C, and human immunodeficiency virus infection
- active or untreated latent tuberculosis
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Placebo
VIB4920 75 mg
VIB4920 500 mg
VIB4920 1000 mg
VIB4920 1500 mg
Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.